Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s MHLW Asks Local Governments To Add Relenza To Flu Drug Stockpile

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor and Welfare will require prefecture governments to stockpile 10 percent Relenza (zanamivir) starting fiscal year 2009. The decision is based on a recent Yomiuri News survey that finds out of 47 local governments, 46 prefectures stock nothing but Tamiflu (oseltamivir) and only Tokyo has Relenza in stock. The ministry is concerned about recent Tamiflu-resistant cases and has ordered additional Relenza shipments. Japan has stockpiled Tamiflu for 280 million people, and will add 133 million doses. The country also has 1.35 million doses of Relenza in stock and plans to order an additional 1.33 million doses. Tokyo's prefecture government has decided to increase flu drug stockpiles to 8 million doses by 2010, and half will be Relenza. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel